Michael W. Bishop

ORCID: 0000-0003-3926-1446
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Sarcoma Diagnosis and Treatment
  • Childhood Cancer Survivors' Quality of Life
  • Neuroblastoma Research and Treatments
  • Organometallic Complex Synthesis and Catalysis
  • Cancer, Hypoxia, and Metabolism
  • Testicular diseases and treatments
  • Magnetism in coordination complexes
  • Bone Tumor Diagnosis and Treatments
  • Metal complexes synthesis and properties
  • Glioma Diagnosis and Treatment
  • Adrenal and Paraganglionic Tumors
  • CAR-T cell therapy research
  • Inorganic Chemistry and Materials
  • Metalloenzymes and iron-sulfur proteins
  • Palliative Care and End-of-Life Issues
  • Acute Lymphoblastic Leukemia research
  • Organometallic Compounds Synthesis and Characterization
  • Cancer therapeutics and mechanisms
  • Crystal structures of chemical compounds
  • Lymphoma Diagnosis and Treatment
  • Renal and related cancers
  • Cardiac tumors and thrombi
  • Metal-Catalyzed Oxygenation Mechanisms
  • Surgical site infection prevention
  • Advanced Frequency and Time Standards

Arkansas Children's Hospital
2025

St. Jude Children's Research Hospital
2015-2024

U.S. Air Force Institute of Technology
2021

University of Tennessee Health Science Center
2015-2020

Kirtland Air Force Base
2018-2019

United States Air Force Research Laboratory
2018

Memorial Sloan Kettering Cancer Center
2018

Children's National
2017

Memphis Health Center
2014

Children's Hospital of Los Angeles
2013

Long-term follow-up data on premature ovarian insufficiency (POI) in childhood cancer survivors are limited. To describe the prevalence of POI, its risk factors, and associated long-term adverse health outcomes. Cross-sectional. The St. Jude Lifetime Cohort Study, an established cohort a tertiary care center. Nine hundred twenty-one participants (median age, 31.7 years) were evaluated at median 24.0 years after diagnosis. POI was defined by persistent amenorrhea combined with...

10.1210/jc.2016-3723 article EN The Journal of Clinical Endocrinology & Metabolism 2017-03-24

Optical frequency standards surpass their microwave counterparts in both stability and accuracy, yet they are often bulky, power-hungry, unable to operate outside of a well-controlled laboratory environment. Leveraging two-photon transition ${}^{87}$Rb vapor recent advances fiber combs, the authors build an optical clock beat current portable standards, with architecture that can be made compact low-power. These results point way real-world standard even higher stability, for applications...

10.1103/physrevapplied.9.014019 article EN Physical Review Applied 2018-01-18

Background Bone scintigraphy (BS) is used to detect osseous metastases in osteosarcoma. 18F-fluorodeoxyglucose-positron emission tomography–computed tomography (18F-FDG-PET-CT) being increasingly for staging. We compared the sensitivity, specificity, and diagnostic accuracy of 18F-FDG–PET-CT BS detecting Methods retrospectively reviewed 39 patients with osteosarcoma who had paired PET–CT at diagnosis and/or first recurrence from 2003 2012. Imaging studies were by two pediatric imaging...

10.1002/pbc.26014 article EN Pediatric Blood & Cancer 2016-04-15

Abstract Purpose: We sought to evaluate whether combining a humanized antidisialoganglioside mAb (hu14.18K322A) with induction chemotherapy improves early responses and outcomes in children newly diagnosed high-risk neuroblastoma. Patients Methods: conducted prospective nonrandomized, single-arm, two-stage, phase II clinical trial. Six courses of were coadministered hu14.18K322A followed granulocyte–macrophage colony-stimulating factor (GM-CSF) low-dose IL2. Consolidation was performed...

10.1158/1078-0432.ccr-19-1452 article EN Clinical Cancer Research 2019-10-10

Background The prognostic value of histologic response for osteosarcoma may have changed with induction chemotherapy schedules over time. We hypothesized that the increased intensity therapy provided on INT0133 compared to Children's Cancer Group study CCG‐782 would diminish impact risk events after definitive surgery. Methods Retrospective analysis was performed patients aged <22 newly diagnosed nonmetastatic enrolled and INT0133. Clinical factors were evaluated association outcome. Good...

10.1002/pbc.26034 article EN Pediatric Blood & Cancer 2016-04-29

<h3>Importance</h3> This study provides the first objective data documenting neurocognitive impairment in long-term survivors of childhood osteosarcoma. <h3>Objective</h3> To examine neurocognitive, neurobehavioral, emotional, and quality-of-life outcomes <h3>Design, Setting, Participants</h3> Cross-sectional cohort at an academic research hospital, with prospective treatment chronic health predictors. Outcome were collected from June 2008 to August 2014. Data analysis was completed April...

10.1001/jamaoncol.2015.4398 article EN JAMA Oncology 2015-11-19

Background and Objectives Desmoplastic small round cell tumor (DSRCT) is a rare peritoneal surface malignancy. Current research limited by the scarcity of this disease. Methods Patients with DSRCT were identified in 2004‐2014 NCDB. Factors affecting overall survival (OS) assessed. Additionally, trends examined based on volume cases treated at individual facilities. Results A total 125 patients median age 21 (IQR 15‐27). Six had extra‐abdominal disease 15 (12%) liver involvement. Median OS...

10.1002/jso.25071 article EN Journal of Surgical Oncology 2018-06-01

Direct assessment of Leydig cell function in childhood cancer survivors has been limited. The objectives this study were to describe the prevalence and risk factors for failure (LCF), dysfunction (LCD), associated adverse health outcomes.In retrospective with cross-sectional outcomes analysis, we evaluated 1,516 participants (median age, 30.8 years) at a median 22.0 years after diagnosis. LCF was defined as serum total testosterone less than 250 ng/dL (or 8.67 nmol/L) luteinizing hormone...

10.1200/jco.19.00738 article EN Journal of Clinical Oncology 2019-09-26

Background . Mesenchymal chondrosarcoma is an aggressive, uncommon histologic entity arising in bone and soft tissues. We reviewed our institutional experience with this rare diagnosis. Methods conducted a retrospective chart review on patients mesenchymal over 24-year period. Clinicopathologic radiographic features were reviewed. Results Twelve identified. Nine females; median age was 14.5 years (1.2–19.7 years). The most common site the head/neck (7/12). Disease localized 11/12 (one lung...

10.1155/2015/608279 article EN Sarcoma 2015-01-01

Survivors of lower extremity (LE) malignancies experience functional deficits.The purpose this prospective clinical trial was to determine feasibility and outcomes adding pre-habilitation during the 10-12 week period prior a planned surgery remove tumor in children adolescents with LE sarcoma.Pilot study.St. Jude Children's Research Hospital (SJCRH).Participants included 14 individuals between ages 8 20 years who were diagnosed sarcoma. Participant compared control group 35 treated for...

10.1097/01.reo.0000000000000050 article EN Rehabilitation Oncology 2017-01-01

Background Limb‐sparing surgery for osteosarcoma requires taking wide bony resection margins while maximizing preservation of native bone and joint. However, the optimal margin factors associated with recurrence survival outcomes in these patients are not well established. Procedure We conducted a retrospective review children adolescents newly diagnosed from 1986 to 2012, where limb‐sparing surgeries were decreased serially 5 1.5 cm. The association between other surgicopathological was...

10.1002/pbc.25307 article EN Pediatric Blood & Cancer 2014-11-08

Patients with bilateral Wilms tumor initially receive neoadjuvant chemotherapy to shrink the tumors and increase likelihood of successful nephron-sparing surgery. Biopsy poorly responding is often done better understand therapy resistance. The purpose this retrospective, single-institution study was determine whether initial response associated histology, potentially obviating need for biopsy or change in chemotherapy.

10.1093/jnci/djae072 article EN JNCI Journal of the National Cancer Institute 2024-03-27
Coming Soon ...